Literature DB >> 6416837

Inhibition of bacterial multiplication by the iron chelator deferoxamine: potentiating effect of ascorbic acid.

B S van Asbeck, J H Marcelis, J J Marx, A Struyvenberg, J H van Kats, J Verhoef.   

Abstract

Since iron is essential for the multiplication of microorganisms, the effect of the iron chelator deferoxamine, with or without ascorbic acid, on the growth of 43 strains of Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Alcaligenes faecalis, Neisseria meningitidis and species of Salmonella, Enterobacter, Pseudomonas and Providencia, was investigated with the use of an automated turbidimeter. Addition of deferoxamine (25-400 micrograms/ml) to the incubation medium was inhibitory in a dose-dependent fashion. At concentrations between 200-400 micrograms/ml, growth was about 25% lower than control values. However, when ascorbic acid (100 micrograms/ml) was added to the culture medium, this antimicrobial activity of deferoxamine was significantly increased to on average 75% of the control value (p less than 0.05). Ascorbic acid alone had no bacteriostatic properties. Growth in the presence of 200 micrograms/ml deferoxamine combined with 100 micrograms/ml ascorbic acid was significantly lower than that in control media without additions (p less than 0.001). Addition of ferric citrate to the culture medium at a concentration sufficient to saturate all of the deferoxamine with iron, abolished the growth inhibiting effect of deferoxamine. The results provide evidence that deferoxamine is bacteriostatic due to its capacity to deplete iron which would otherwise be used for bacterial multiplication, and that ascorbic acid enhances this antibacterial property of deferoxamine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6416837     DOI: 10.1007/BF02013899

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  27 in total

1.  CHELATION OF FERROUS SULPHATE SOLUTIONS BY DESFERRIOXAMINE B.

Authors:  J F GOODWIN; C F WHITTEN
Journal:  Nature       Date:  1965-01-16       Impact factor: 49.962

2.  Salmonellosis--a review of some unusual aspects.

Authors:  P H BLACK; L J KUNZ; M N SWARTZ
Journal:  N Engl J Med       Date:  1960-04-21       Impact factor: 91.245

3.  Salmonella osteomyelitis and abnormal hemoglobin disease.

Authors:  H K SILVER; J L SIMON; D H CLEMENT
Journal:  Pediatrics       Date:  1957-09       Impact factor: 7.124

4.  Isolation of Yersinia pseudotuberculosis serotype V from the blood of a patient with sickle-cell anaemia.

Authors:  J M Bradley; J I Skinner
Journal:  J Med Microbiol       Date:  1974-08       Impact factor: 2.472

5.  Infection and iron overload in thalassemia.

Authors:  L Caroline; P J Kozinn; F Feldman; F H Stiefel; H Lichtman
Journal:  Ann N Y Acad Sci       Date:  1969-11-20       Impact factor: 5.691

Review 6.  Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.

Authors:  A W Nienhuis; C Delea; R Aamodt; F Bartter; W F Anderson
Journal:  Birth Defects Orig Artic Ser       Date:  1976

7.  Treatment of iron storage disorders.

Authors:  J W Halliday; M L Bassett
Journal:  Drugs       Date:  1980-09       Impact factor: 9.546

Review 8.  Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature.

Authors:  E Barrett-Connor
Journal:  Medicine (Baltimore)       Date:  1971-03       Impact factor: 1.889

Review 9.  The significance of iron in infection.

Authors:  J J Bullen
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

10.  Facilitation of Fe(II) autoxidation by Fe(3) complexing agents.

Authors:  D C Harris; P Aisen
Journal:  Biochim Biophys Acta       Date:  1973-11-02
View more
  8 in total

1.  In vitro antimicrobial properties of deferoxamine mesylate.

Authors:  D J Flournoy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

2.  Media for study of growth kinetics and envelope properties of iron-deprived bacteria.

Authors:  J L Kadurugamuwa; H Anwar; M R Brown; G H Shand; K H Ward
Journal:  J Clin Microbiol       Date:  1987-05       Impact factor: 5.948

3.  Synergy between the iron chelator deferoxamine and the antimicrobial agents gentamicin, chloramphenicol, cefalothin, cefotiam and cefsulodin.

Authors:  B S van Asbeck; J H Marcelis; J H van Kats; E Y Jaarsma; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

4.  Biofilm-specific uptake of a 4-pyridone-based iron chelator by Pseudomonas aeruginosa.

Authors:  Sharareh Houshmandyar; Ian M Eggleston; Albert Bolhuis
Journal:  Biometals       Date:  2021-01-11       Impact factor: 2.949

5.  Effect of iron-chelator deferiprone on the in vitro growth of staphylococci.

Authors:  Choon-Mee Kim; Sung-Heui Shin
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

6.  QSAR study of antimicrobial 3-hydroxypyridine-4-one and 3-hydroxypyran-4-one derivatives using different chemometric tools.

Authors:  Razieh Sabet; Afshin Fassihi
Journal:  Int J Mol Sci       Date:  2008-12-02       Impact factor: 6.208

Review 7.  Immunomodulatory and Antimicrobial Effects of Vitamin C.

Authors:  Soraya Mousavi; Stefan Bereswill; Markus M Heimesaat
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2019-08-16

8.  In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria.

Authors:  Lucie Peyclit; Sophie Alexandra Baron; Linda Hadjadj; Jean-Marc Rolain
Journal:  Antibiotics (Basel)       Date:  2022-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.